The Pharmacy Times® Respiratory Syncytial Virus Resource Center is a comprehensive source for clinical news and expert insights on treating and preventing respiratory syncytial virus.
April 30th 2024
Prevention of acute cardiac events may be another consideration for future postlicensure studies of RSV vaccines.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Access, and Adherence
1.5 Credits / HIV/AIDS, Infectious Disease
View More
Considerations for RSV Prevention in Special Patient Populations
February 2nd 2024Older adults, patients with weakened immune systems, individuals living in long-term facilities, and those with underlying cardiopulmonary disease are at a higher risk of developing severe RSV infection outcomes.
Read More
Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.
Read More